SomaLogic Announces Appointment of Shaun Blakeman as Director


NEW YORK and BOULDER, Colo., Aug. 02, 2021 (GLOBE NEWSWIRE) — CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, a leader in AI data-driven proteomics technology, today announced the appointment of Shaun Blakeman as the company’s chief financial officer.

“We are delighted to welcome Shaun Blakeman to the SomaLogic team,” said Roy Smythe, CEO of SomaLogic. “His extensive experience as CFO in various medical technology companies greatly strengthens our leadership team and will have an immediate impact. as we continue to rapidly grow our business. »

Mr. Blakeman is a finance executive with over 20 years of professional experience spanning operations, logistics, project management, and accounting and finance leadership. Most recently, he served as Senior Vice President and Chief Financial Officer of Cantel Medical, a public company focused on infection prevention and control globally in the areas of endoscopy, hemodialysis and dental care.

Mr. Blakeman also served as senior chief financial officer at Medtronic, a medical technology leader, where he oversaw finance for several manufacturing sites in Medtronic’s Restorative Therapies Group. Prior to that, he was vice president of finance at Cantel, where he was the segment chief financial officer for the company’s $500 million endoscopy platform. Prior to joining Cantel, Mr. Blakeman spent five years at IDEX in progressively responsible finance leadership roles, eventually serving as Vice President of Finance for Diaphragm and Metering Pumps and Water Platforms. the company. Prior to IDEX, Mr. Blakeman worked for Eaton in various finance roles. He began his career as an officer in the United States Navy in surface warfare and engineering specialties.

Mr. Blakeman received his Bachelor of Science in Economics from the University of Minnesota, his Master of Science in Applied Physics from the Naval Postgraduate School and his Master of Business Administration from Indiana University Kelley School of Business.

“SomaLogic is a pioneer in the development of proteomics for biomarker discovery and clinical insights,” said Blakeman. “I am honored to join the organization on the path to improving global healthcare outcomes for patients around the world. »

About SomaLogic
SomaLogic seeks to provide accurate, meaningful and actionable health management insights that enable individuals around the world to continuously optimize their personal health and well-being throughout their lives. This critical information, to be provided through a global network of partners and users, is derived from SomaLogic’s custom measurement of significant changes in an individual’s proteins over time. For more information, visit and follow @somalogic on Twitter.

SomaSignal™ assays are developed and their performance characteristics determined by SomaLogic, Inc. SomaLogic is a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory accredited by the College of American Pathologists (CAP). The tests have not been authorized or approved by the United States Food and Drug Administration.

The SomaScan Assay™ is for research use only (RUO) and has not been cleared or approved by the United States Food and Drug Administration for diagnostic or patient management purposes.

Disclaimer of Forward-Looking Statements
Certain matters discussed throughout this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Generally, our use of words such as “expect”, “anticipate”, ” believe”, “estimate”, “intend”, “strategy”, “future”, “opportunity”, “will”, “expect”, “plan”, “project”, “assume”, or similar words regarding the future identify such forward-looking statements. These forward-looking statements are based on current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to the Company. These statements may relate to the Company’s revenue, earnings and other business plan projections, financial and operating measures, the Company’s indebtedness levels, the ability to repay outstanding debt, the payment of dividends and future transactions, among others. We caution you not to place undue reliance on these forward-looking statements. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors. Forward-looking statements speak only as of the date they are made. You are cautioned not to place undue reliance on forward-looking statements.

Contact Soma Logic
Emilie Costales
[email protected]

Contact Investor
Lynn Lewis or Marissa Bych
Gilmartin Group LLC
[email protected]


Comments are closed.